生物科技公司ImmunityBio（IBRX）在夜盘交易中股价大跌5.63%，引发市场关注。这一显著跌幅与公司最新发布的2025财年第一季度财务报告密切相关。
根据ImmunityBio公布的财报，公司2025财年第一季度净亏损为1.30亿美元，虽然同比收窄2.99%，但仍然处于大幅亏损状态。值得注意的是，公司营业收入达到1652万美元，同比大幅增长41200%。每股基本亏损为0.15美元。从资产负债表来看，公司总负债为8.94亿美元，其中短期债务为746万美元，资产负债比为0.35，流动比率仅为0.03。
尽管ImmunityBio的营收出现显著增长，但持续的亏损状况可能是导致投资者信心下降的主要原因。作为一家专注于开发下一代免疫和细胞疗法的临床阶段生物科技公司，ImmunityBio的研发投入可能仍然较高。此外，相对较低的流动比率也可能引发了市场对公司短期偿债能力的担忧。这些因素综合作用，可能导致了夜盘交易中的股价大跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.